Animal models, screening methods, and treatment methods for intraocular diseases or disorders
Provided herein are screening methods and animal models related to intraocular diseases such as age-related macular degeneration (AMD), for example, for identifying candidate therapeutics for treating or preventing eye diseases, such as AMD. Also provided herein are compounds/compositions that are useful for killing or inhibiting the growth of a microorganism, such as Bacillus megaterium . Further provided herein are methods of using the compounds/compositions for treating infections with a microorganism, such as Bacillus megaterium and for treating or preventing diseases or disorders associated with such infections, such as AMD.
1. A method comprising:
(i) identifying, or having identified, a subject as being infected with a microorganism in the intraocular space, wherein the subject has age-related macular degeneration (AMD); and
(ii) administering to the subject a therapeutically effective amount of an active compound selected from one of compounds (1)-(8) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the active compound or pharmaceutically acceptable salt thereof, wherein compounds (1)-(8) have the following chemical structures:
wherein the therapeutically effective amount is an amount effective in killing or inhibiting the growth of the microorganism in the intraocular space.
2. The method of claim 1 , wherein the microorganism comprises Bacillus megaterium.
3. The method of claim 1 , wherein the microorganism comprises one or more species selected from Staphylococcus epidermidis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas putida, Stenotrophomonas maltophilia, Bacillus cereus, Bacillus megaterium, Lactobacillus reuteri, Gardnerella vaginalis, Enterococcus faecium, Cytophaga hutchinsonii, Bacillus licheniformis , and Xanthomonas oryzae.
4. The method of claim 1 , wherein the active compound is compound (6):
5. The method of claim 1 , wherein the administering is an oral administration.
6. The method of claim 1 , wherein the administering is carried out topically, intravitreously, intramuscularly, subcutaneously, or intravenously.
7. A method for ameliorating age-related macular degeneration (AMD) in a subject in need thereof, comprising:
(i) identifying, or having identified, the subject as being infected with a microorganism in the intraocular space, wherein the microorganism comprises Bacillus megaterium ; and
(ii) administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an active compound selected from compound (6) or a pharmaceutically acceptable salt thereof, wherein compound (6) is:
8. The method of claim 7 , wherein the AMD is a dry or wet age-related macular degeneration with drusen symptoms.
9. The method of claim 8 , wherein the drusen symptoms include a hard drusen, a soft drusen, a mixed drusen, and/or a degraded drusen.
10. The method of claim 8 , wherein the AMD is dry or wet age-related macular degeneration with soft drusen symptoms.
11. The method of claim 7 , wherein the pharmaceutical composition is administered in an amount effective for killing or inhibiting the growth of the microorganism in the intraocular space.
12. The method of claim 7 , wherein the pharmaceutical composition is administered orally.
13. The method of claim 7 , wherein the pharmaceutical composition is administered topically, intravitreously, intramuscularly, subcutaneously, or intravenously.
14. A method for ameliorating age-related macular degeneration (AMD) in a subject infected with a microorganism in the intraocular space, the method comprising killing or inhibiting the growth of the microorganism in the intraocular space by administering to the subject an effective amount of a pharmaceutical composition comprising an active compound selected from compound (6), wherein the microorganism comprises Bacillus megaterium , and wherein compound (6) is:
15. The method of claim 14 , wherein the AMD is a dry or wet age-related macular degeneration with drusen symptoms.
16. The method of claim 15 , wherein the drusen symptoms include a hard drusen, a soft drusen, a mixed drusen, and/or a degraded drusen.
17. The method of claim 15 , wherein the AMD is dry or wet age-related macular degeneration with soft drusen symptoms.
18. The method of claim 14 , wherein the pharmaceutical composition is administered orally.
19. The method of claim 14 , wherein the pharmaceutical composition is administered topically, intravitreously, intramuscularly, subcutaneously, or intravenously.
20. The method of claim 14 , wherein the pharmaceutical composition is administered intravitreously.